Factor V Leiden and other hypercoagulable state mutations are not associated with osteonecrosis during or after treatment for pediatric malignancy

Journal of Pediatrics

Volumn 134, Issue 3, 1999, Pages 310-314

  Kechli, Amer M ^a   Wilimas, Judith A ^a   Pui, Ching Hon ^a   Park, Vicki M ^a   Tonkel, Stacey ^a   Deitcher, Steven R ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CORTICOSTEROID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE NECROSIS; CASE REPORT; CHILDHOOD CANCER; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HYPERCOAGULABILITY; JAW DISEASE; MALE; PERTHES DISEASE; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; STEROID THERAPY; THROMBOPHILIA;

EID: 0033512836     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(99)70455-5     Document Type: Article

References (25)

1. 1. Usher BW Jr, Friedman RJ. Steroid-induced osteonecrosis of the femoral head. Orthopedics 1995;18:47-51.
2. 2. Hanif I, Mahmoud H, Pui CH. Avascular femoral head necrosis in pediatric cancer patients. Med Pediatr Oncol 1993;21:655-60.
3. 3. Murphy RG, Greenberg ML. Osteonecrosis in pediatric patients with acute lymphoblastic leukemia. Cancer 1990;65:1717-21.
4. 4. Felix C, Blatt J, Goodman MA, Medina J. Avascular necrosis of bone following combination chemotherapy for acute lymphocytic leukemia. Med Pediatr Oncol 1985;13:269-72.
5. 5. Bomelburg T, von Lengerke HJ, Ritter J. Aseptic necrosis in the treatment of childhood acute leukemias. Eur J Pediatr 1989;149:20-3.
6. 6. Nachman J, Sather HN, Gaynon PS, Lukens JN, Wolff L, Trigg ME. Augmerited Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lympl̃oblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. J Clin Oncol 1997;15:2222-30.
7. 7. Ojala AE, Lanning FP, Paakko E, Lanning BM. Osteonecrosis in children treated for acute lymphoblastic leukemia: a magnetic resonance imaging study after treatment. Med Pediatr Oncol 1997;29:206-65.
8. 8. Glimcher MJ, Kenzora, JE. The biology of osteonecrosis of the human femoral head and its clinical implications. II. The pathological changes in the femoral head as an organ and in the hip joint. Clin Orthop 1979;139:283-312.
9. 9. Liu SL, Ho TC. The role of venous hypertension in the pathogenesis of Legg-Perthes disease. A clinical and experimental study. J Bone Joint Surg Am 1991;73A:194-200.
10. 10. Jones JP Jr. Intravascular coagulation and osteonecrosis. Clin Orthop 1992;277:41-53.
11. 11. Gruppo R, Glueck CJ, McMahon RE, Bouquot J, Rabinovich BA, Becker A, et al. The pathophysiology of alveolar osteonecrosis of the jaw: anticardiolipin antibodies, thrombophilia, and hypofibrinolysis. J Lab Clin Med 1996;127:481-8.
12. 12. Glueck CJ, Brandt G, Gruppo R, Crawford A, Roy D, Tracy T, et al. Resistance to activated protein C and Legg-Perthes disease. Clin Orthop 1997;338:139-52.
13. 13. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-8.
14. 14. Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor V R506Q. J Biol Chem 1995;270:4053-7.
15. 15. Dahlback B. Molecular genetics of thrombophilia: factor V gene mutations causing resistance to activated protein C as a basis of the hypercoagulable state. J Lab Clin Med 1995;125:566-71.
16. 16. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
17. 17. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
18. 18. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747-50.
19. 19. Armda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzachi JM, Costa FF. The mutation Ala677→Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997;77:818-21.
20. 20. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995;10:111-3.
21. 21. Balasa V, Gruppo RA, Glieck CJ, Becker A, Pillow A, Stroop D, et al. Mutations in the methylenetetrahydrofolate reductase, prothrombin and plasminogen activator inhibitor-1 genes and homocysteine, prothrombin, and plasminogen activator inhibitor-1 levels in 197 healthy children and 40 healthy adults. J Pediatr Hematol Oncol 1998;20:370-1.
22. 22. Glueck CJ, McMahon RE, Bouquot JE, Triplett D, Gruppo R, Wang P. Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens. J Lab Clin Med 1997;130:540-3.
23. 23. Guttormsen AB, Ueland PM, Nesthus I, Nygiird O, Schneede J, Vollset SE. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> 40 μmol/liter). J Clin Invest 1996;98:2174-83.
24. 24. Kucuk O, Kwaan HC, Gunnar W, Vazquez RM. Thromboembolic complications associated with L-asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma. Cancer 1985;55:702-6.
25. 25. Hanada T, Horigome Y, Inudoh M, Takita H. Osteonecrosis of vertebrae in a child with acute lymphocytic leukemia during L-asparaginase therapy. Eur J Pediatr 1989;149:162-3.